Eravacycline (TP-434, Xerava) is a synthetic halogenated tetracycline class antibiotic by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) were recently completed with mixed results. Eravacycline was granted fast track designation by the FDA and is currently available in USA. Medical uses
Eravacycline has shown broad spectrum of activity against a variety of Gram-positive and Gram-negative bacteria, including multi-drug resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae. It is currently being formulated as for intravenous and oral administration. Spectrum of activity
Gram-positive organisms
Staphylococcus aureus (both methicillin-resistant and sensitive strains)
Streptococcus pneumoniae
Enterococcus faecalis
Enterococcus faecium (including vancomycin resistant strains)

Gram-negative organisms
Acinetobacter baumannii
Stenotrophomonas maltophilia
Haemophilus influenzae
Moraxella catarrhalis
Neisseria gonorrhoeae
Enterobacteriaceae
Escherichia coli (including ESBL-producing strains)
Klebsiella pneumoniae (including carbapenem resistant strains)
Klebsiella oxytoca
Enterobacter species
Citrobacter species
Proteus mirabilis
Serratia marcescensSimilar to other tetracycline derivatives, eravacycline is poorly active against Pseudomonas aeruginosa with a MIC90 = 16 mcg/mL (range 0.06-64 mcg/mL). Eravacycline maintains in-vitro activity against Enterobacteriaceae carrying the mcr-1 gene responsible for polymyxin b/colistin resistance. Clinical trials
Current and past clinical trial information:
https://clinicaltrials.gov/ct2/results?cond=&term=eravacycline&cntry1=&state1=&recrs=

Phase 3 trials
Complicated Intra-abdominal infections (IGNITE 1)
The IGNITE 1 trial compared twice-daily IV eravacycline to once-daily ertapenem for the treatment of cIAI. A total of 541 patients were included and eravacycline demonstrated noninferiority to ertapenem. An additional pivotal phase 3 study (IGNITE 4) is planned for late 2016 with initial results likely available in the fourth quarter of 2017.
Nevus spilus, also known as speckled lentiginous nevus, is a light brown or tan birth mark, speckled with small, dark spots or small bumps. If it occurs in a segmental pattern then it is sometimes referred to as a Zosteriform speckled lentiginous nevus.It may be associated with types of phakomatosis pigmentovascularis.Prevalence is between 0.2% and 2.8%. See also
Phakomatosis pigmentokeratotica
Skin lesion
List of cutaneous conditions

References


== External links ==